Journal Logo

July 25th, 2003 - Volume 25 - Issue 14
pp: 4-73


Dire Predictions about Cancer Care for Medicare Patients If Proposed Reform Bills Are Passed

Fromer, Margot J.

Oncology Times. 25(14):5-6, July 25th, 2003.

The groups condemned provisions in both the House and Senate Medicare prescription drug bills that would severely cut Medicare coverage for chemotherapy and other critical cancer care for the 700,000 Medicare beneficiaries diagnosed with cancer each year.

Prostate Cancer Prevention Trial Findings Predicted to Have Little Influence on Practice

Susman, Ed

Oncology Times. 25(14):14-15, July 25th, 2003.

The SWOG study of 4,692 men concluded that finasteride prevents or delays the appearance of prostate cancer, but that this possible benefit and a reduced risk of urinary problems must be weighed against sexual problems and an increased risk of high-grade prostate cancer.

Susan B. Horwitz, PhD, Finishes Term (Plus!) As AACR President

Klein, Joan

Oncology Times. 25(14):41-42, July 25th, 2003.

The paclitaxel pioneer talks about her unexpectedly long tenure as President of AACR, which included the rescheduling of the annual meeting and the con-troversy about Cornelius P. Rhoads, gives advice to young researchers, and discusses the organization's beginning dialogue with the FDA about chemopre-vention and surrogate endpoints.

Microarrays: What They Are, How They Work

Tuma, Rabiya S.

Oncology Times. 25(14):48-51, July 25th, 2003.

This periodic feature will describe new tech-nologies, moving beyond the jargon to explain, amplify, and give examples of good resources. This time: Microarrays: What They Are, How They Work

CNS Metastases: New Options for Earlier Diagnosis & Effective Management

Goodman, Alice

Oncology Times. 25(14):55-58, July 25th, 2003.

Earlier diagnosis and more effective management are offering a more positive outlook for this devas-tating problem.

IRIS Trial: Patients Benefit, But Survival Questions Remain

Henkel, Gretchen

Oncology Times. 25(14):65-66, July 25th, 2003.

Although early release of data from this international randomized trial of interferon and imatinib at ASCO's 2002 Annual Meeting was hailed as a big advance for leukemia patients, one of the study's lead investigators initially had reservations about reporting 12-month follow-up data.